Parmax Pharma Limited, a pharmaceutical company specializing in bulk drugs, drug intermediates, and specialty chemicals, has reported substantial financial losses for the half-year ended September 30, 2025. The company's board recently approved the unaudited standalone financial results, revealing a challenging period for the organization.

Key Financial Highlights

Revenue Growth Overshadowed by Increased Expenses

Despite a notable increase in revenue from operations, rising by 21.25% to Rs 447.32 crore compared to Rs 368.92 crore in the previous year, Parmax Pharma's financial performance was significantly impacted by a disproportionate rise in expenses. The total expenses surged by 28.01% to Rs 732.97 crore, outpacing the revenue growth and resulting in a substantial net loss.

Widening Losses

The company reported a net loss of Rs 284.29 crore for the half-year, marking a 40.69% increase from the loss of Rs 202.07 crore in the corresponding period of the previous year. This widening loss has led to a negative basic earnings per share (EPS) of Rs 7.60, compared to Rs 5.40 in the previous year.

Operational Challenges

The unaudited financial results indicate ongoing operational challenges for Parmax Pharma. The significant increase in expenses, particularly in areas such as cost of materials consumed and finance costs, suggests potential issues with operational efficiency and financial management.

Auditor's Notes

In the limited review report, the auditors highlighted two key points:

1. The company is awaiting a surveyor's report for a fire incident that occurred in December 2023. A claim of Rs 3.50 crore has not yet been submitted to the insurance company due to the pending report.

2. The company has not provided depreciation on clean room plant and effluent treatment plant, considering the non-usage of these assets.

These notes suggest potential areas of concern regarding asset management and insurance claims that may impact future financial statements.

Looking Ahead

As Parmax Pharma grapples with these financial challenges, stakeholders will be keenly watching for any strategic initiatives or operational changes the company might implement to address the widening losses and improve its overall financial health in the coming quarters.

Parmax Pharma Limited, a pharmaceutical company, has released its audited financial results for the quarter and year ended March 31, 2023, revealing a mixed performance with a notable decline in revenue.

Quarterly Performance

For the quarter ended March 31, 2023, Parmax Pharma reported:

• Revenue from operations: Rs 63,819.33 thousand
• Net profit: Rs 1,729.60 thousand

The company's quarterly revenue saw a decrease compared to the same period in the previous year, which stood at Rs 70,879.78 thousand.

Annual Financial Results

For the full fiscal year 2023, Parmax Pharma's financial performance showed:

• Revenue: Rs 154,243.45 thousand (down from Rs 182,511.20 thousand in FY 2022)
• Net loss: Rs 1,040.68 thousand (compared to a profit of Rs 1,415.13 thousand in FY 2022)
• Total expenses: Rs 154,179.43 thousand

The company's balance sheet revealed total assets of Rs 176,126.31 thousand as of March 31, 2023.

Audit Opinion

The statutory auditors, B.A. Shah S.R. Mehta & Co, have issued an unmodified opinion on the financial results, indicating that the financial statements present a fair view of the company's financial position and performance.

Recent Financial Trends

Based on the latest available financial data:

Conclusion

Parmax Pharma Limited's financial results for FY 2023 highlight a challenging year for the company, marked by a decline in revenue and a shift from profit to loss on an annual basis. While the company managed to post a profit in the last quarter, the overall annual performance indicates ongoing financial pressures.